Forecasting & Assessment – 3 Items

1. Dose 3 PCV should forecast for at least 12 months of age and at least 8 weeks as final dose if previous dose is 7-11 months of age. (Ref# 292)

2. Td/Tdap booster should be 10 years for accelerated date. (Ref# 2588)

3. Update RSV MAB forecasting and evaluation, review RSV vaccine for 24-25 season will become effective on 4/1/2024 (Ref# 2767)
   - RSV season is defined as October 1, 2024, through March 31, 2024, for 0 to 8 months of age.
   - Doses given to infants with special situations, who are 8 -19 months, will be accepted and displayed as Other Administrations.
   - RSV vaccine forecast for unvaccinated adults 60 years and older was updated changed to 9/1/24 (late summer or early fall) for unvaccinated adults
   - For more information, go to https://www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html.
Please review the links provided below for the updated CDC information.

- RSV (Respiratory Syncytial Virus) Immunizations | CDC
- RSV Vaccination: What Older Adults 60 Years of Age and Over Should Know | CDC
- Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over | CDC
- Frequently Asked Questions About RSV Vaccine for Adults | CDC
- Preventing RSV (Respiratory Syncytial Virus) | CDC
- RSV in Older Adults and Adults with Chronic Medical Conditions | CDC
- For Healthcare Professionals: RSV (Respiratory Syncytial Virus) | CDC

General - 2 items

1. CVX 30 HepB IG manufacturer’s list has been updated to add **Grifols** Therapeutics. (Ref# 2795)

2. The issue with HL7 Rejection resulting in deduction from Beyfortus inventory has been resolved. (Ref# 2744)

   Upon receipt of a rejection messages, the information will not appear on the patient’s record or deduct from inventory.

   If you have questions or need assistance, please contact your Field Representative or **MCIR SOM Help Desk** at MDHHS-MCIRHelp@michigan.gov.